Redeye believes current valuation implies a too cautious view of Abliva’s project portfolio. Early evidence and positive regulatory feedback validate the development of lead candidate KL1333 in primary mitochondrial disease, an untapped orphan drug opportunity. A key element to further successful clinical development and hence rerating, in our opinion, is if Abliva can secure additional financing.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/